Genmab A/S (OTCMKTS:GNMSF - Get Free Report)'s stock price gapped up before the market opened on Wednesday . The stock had previously closed at $208.80, but opened at $225.00. Genmab A/S shares last traded at $225.00, with a volume of 25 shares traded.
Genmab A/S Stock Performance
The company's 50 day moving average is $211.43 and its 200 day moving average is $206.17. The stock has a market capitalization of $14.87 billion, a price-to-earnings ratio of 12.76 and a beta of 0.91.
Genmab A/S (OTCMKTS:GNMSF - Get Free Report) last announced its earnings results on Thursday, May 8th. The company reported $3.05 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.88 by $1.17. Genmab A/S had a net margin of 35.11% and a return on equity of 19.23%. The business had revenue of $765.14 million for the quarter, compared to analyst estimates of $761.09 million.
Genmab A/S Company Profile
(
Get Free Report)
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.
Further Reading
Before you consider Genmab A/S, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Genmab A/S wasn't on the list.
While Genmab A/S currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.